Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a price target of $38.
October 09, 2023 | 3:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Aclaris Therapeutics and maintained a price target of $38.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Aclaris Therapeutics. The maintained price target of $38 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100